116247-91-7

Basic information

• Product Name: 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane
• Synonyms: 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane
• CAS NO: 116247-91-7
• Molecular Formula: C11H15N3O2
• Molecular Weight: 221.2557
• Mol File: 116247-91-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane(116247-91-7)
• EPA Substance Registry System: 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane(116247-91-7)

Safety Data

• Hazardous Substances Data: 116247-91-7(Hazardous Substances Data)

Usage

General Description

8-(Pyrimidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane is a chemical compound with a unique and complex structure. It contains a pyrimidine ring, two oxygen atoms, and an azaspirodecane moiety. 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane may have potential applications in medicinal chemistry and drug development due to its structural features. The presence of a pyrimidine ring suggests potential biological activity, as pyrimidines are found in many biologically active molecules. The complex spirodecane structure may also provide unique pharmacological properties. Further research and exploration of this compound's chemical and biological properties could reveal potential applications in the pharmaceutical industry.

Upstream product

• 1722-12-9 2-chloropyrimidine 
• 584-08-7 potassium carbonate 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 4595-60-2 2-bromopyrimidine 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

2-heterocyclobenzo[B][1,6]naphthyridines as inhibitors of interleukin

There are disclosed compounds of the formula STR1 wherein R1 is pyridl, quinolinyl, pyrazinyl, pyridinyl, pyridazinyl, pyrimidinyl, quinoxalinyl, quinazolinyl or any of the foregoing substituted with halo, lower alkyl, lower alkyl carbonyl, ben